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Abstract 
Background: Plasmodium knowlesi is the most common cause of malaria in Malaysia. However, microscopic diagno-
sis is inaccurate and rapid diagnostic tests (RDTs) are insufficiently sensitive. PCR is sensitive and specific but not fea-
sible at a district level. Loop-mediated isothermal amplification (LAMP) shows potential with only basic requirements. 
A commercially available LAMP assay, the Eiken Loopamp™ MALARIA Pan Detection kit, is sensitive for Plasmodium 
falciparum and Plasmodium vivax, but has not previously been evaluated for P. knowlesi. This study aims to determine 
the sensitivity of this LAMP assay for detecting P. knowlesi infection.
Methods: Study participants included 73 uncomplicated malaria patients with PCR species confirmation: 50 P. 
knowlesi, 20 P. falciparum and 3 P. vivax. Nineteen malaria-negative, non-endemic area controls were also included. 
The sensitivity of the Eiken Loopamp™ MALARIA Pan Detection kit (Pan LAMP) for detecting each Plasmodium species 
was evaluated. Sensitivity and specificity of the Eiken Loopamp™ MALARIA Pf Detection kit (Pf LAMP) for P. falciparum 
were also determined. The limit of detection for each LAMP assay was evaluated, with results compared to PCR. All P. 
knowlesi patients were also tested by CareStart™ (Pf/VOM) and OptiMAL-IT™ (Pan/Pf ) RDTs.
Results: The sensitivity of the Pan LAMP assay was 100% for P. knowlesi (95% CI 92.9–100), P. falciparum (95% CI 
83.2–100), and P. vivax (95% CI 29.2–100). The Pf LAMP was 100% sensitive and specific for P. falciparum detection, with 
all P. knowlesi samples having a negative reaction. LAMP sensitivity was superior to both RDTs, with only 10 and 28% 
of P. knowlesi samples testing positive to CareStart™ and OptiMAL-IT™, respectively. Limit of detection using the Pan 
LAMP for both P. knowlesi and P. vivax was 2 parasites/μL, comparable to PCR. For P. falciparum both the Pan LAMP and 
Pf LAMP demonstrated a limit of detection of 20 parasites/μL.
Conclusions: The Eiken Loopamp™ MALARIA Pan Detection kit is sensitive for detection of P. knowlesi in low para-
sitaemia clinical infections, as well as P. falciparum and P. vivax. However, a P. knowlesi-specific field assay in a simpler 
format would assist correct species identification and initiation of optimal treatment for all malaria patients.
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Background
Plasmodium knowlesi has emerged as the most common 
cause of malaria infection in Malaysia [1–3]. It can cause 
severe and fatal disease and, due to its rapid clinical course, 
is important to diagnose and treat early [4–8]. Microscopy 
is the diagnostic method of choice in Malaysia but has 
limitations for P. knowlesi as ring stages resemble Plasmo-
dium falciparum and later trophozoites resemble Plasmo-
dium malariae [8–10], hence misidentification is common. 
P. knowlesi causes fever at low parasitaemia [4, 6] and, 
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therefore, may be undetected by microscopy. Better meth-
ods for the diagnosis of knowlesi malaria are needed.
There have been no immunochromatographic rapid 
diagnostic tests (RDTs) specifically designed for P. knowlesi 
detection. Commercially available RDTs measuring an 
antibody response to non-specific pan malarial antigens, 
combined with the variable cross-reactive response of P. 
knowlesi to Plasmodium vivax or P. falciparum-designed 
antigen capture test components have been investigated 
previously [11–13]. However, the sensitivity of these RDTs 
for P. knowlesi detection is poor, particularly at low parasi-
taemia, and they are not currently suitable for clinical use.
Molecular methods, such as PCR, are sensitive and 
specific [14, 15], but are not feasible in many malaria-
endemic areas due to a lack of resources, and do not 
allow rapid diagnosis for correct initiation of treatment. 
Loop-mediated isothermal amplification (LAMP) is a 
promising molecular diagnostic technique that involves 
nucleic acid amplification and target gene detection in 
a single step, and is applicable for use in district hospi-
tal laboratories as it is sensitive, specific and easy to use. 
LAMP does not require expensive reagents or equipment 
and only minimal training is needed [16, 17].
The Eiken Loopamp™ MALARIA Pan Detection kit 
(Pan LAMP) is a field-stable kit suitable for use in rural 
health facilities, designed to detect a non-specific Plas-
modium genus target, and has been shown to be sensitive 
for both P. falciparum and P. vivax, including in clinical 
samples with low parasite counts [18–20]. However, it 
has not previously been validated for the detection of P. 
knowlesi. This study evaluated the sensitivity of the Pan 
LAMP kit in uncomplicated knowlesi malaria using clini-
cal samples to determine whether it might be a useful 
diagnostic or surveillance tool. In addition, the limit of 
detection of this assay was determined for P. knowlesi, P. 
falciparum and P. vivax samples. Finally, the Eiken P. fal-
ciparum-specific LAMP (Pf LAMP) for diagnostic sensi-




This study was conducted with samples collected from 
three sites in Sabah, Malaysia: Kudat District Hospital, 
Kota Marudu District Hospital and Queen Elizabeth 
Hospital in Kota Kinabalu.
Sample collection
Patients with P. knowlesi and P. vivax patients were pro-
spectively enrolled as part of previously reported clinical 
drug trials in three district hospitals in Sabah, Malaysia 
[21, 22]. P. falciparum patients were enrolled as part of an 
ongoing multicentre surveillance study for in vivo artesu-
nate resistance in Sabah.
There were 50 P. knowlesi, 20 P. falciparum and 3 P. 
vivax patients included in the study with PCR-confirmed 
mono-infections, all of whom were microscopy positive 
and enrolled prior to treatment. In addition, 19 healthy 
human volunteers from a non-endemic country (Aus-
tralia) with no previous malaria exposure were included 
as controls after written informed consent. Severe 
malaria was defined according to WHO 2014 guidelines 
[23]. Heparinized whole blood was collected and frozen 
at −80 °C until analysis.
LAMP
The Pan LAMP assay was performed on all clinical 
malaria samples and negative controls, and the Pf LAMP 
on all except the P. vivax samples. The LAMP assays were 
conducted strictly according to the Eiken Loopamp™ 
MALARIA Pan and Pf Detection kit procedures (Eiken 
Chemical Company, Japan). Briefly, DNA was extracted 
using a boil and spin method where 60 μL of thawed, well 
mixed whole blood was added to a labelled tube contain-
ing 60 μL of extraction buffer (400 nM NaCl, 40 mM Tris 
pH 6.5, 0.4% SDS), vortexed and incubated in a heat block 
at 95 °C for 5 min. The tubes were centrifuged at 10,000g 
for 3 min and 30 μL of supernatant was added to 345 μL 
sterile distilled water. After mixing well, 30 μL was added 
to the malaria Pan or Pf reaction tube with one negative 
and one positive control included in each 16 reactions, 
mixed well by inversion to reconstitute primers in the lid 
of the reaction tubes and incubated at 65 °C for 40 min in 
the LA-500 real time turbidimeter (Ref: MVL300—Eiken 
Chemical Co) before polymerase inactivation at 80 °C for 
5 min.
A positive malaria result using the LAMP reaction can 
be visualized as a magnesium pyrophosphate precipitate 
detectable by validated turbidimeter. All reactions were 
also visualized manually by the operator for fluorescence 
and turbidity, with a subsequent reading by a separate 
person blinded to previous LAMP readings and PCR 
results.
PCR
DNA was extracted from 200 μL of blood using Qiagen’s 
QIAamp DNA Blood mini kit™ as per the manufactur-
er’s recommendations. Plasmodium species and limit of 
detection samples were confirmed using a non-multi-
plexed version of the PCR assay previously described by 
Padley et  al. with primers for P. falciparum, P. vivax, P. 
malariae, and P. ovale [24] and for P. knowlesi using the 
PCR method published by Imwong et  al. [14]. All limit 
of detection samples were additionally tested by nested 
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PCR according to the method published by Snounou 
et al. [25].
RDTs
All P. knowlesi patients in this study had whole blood 
tested using both the OptiMAL-IT™ RDT (WHO RDT 
catalogue #710024) containing Plasmodium genus pan-
pLDH and P. falciparum-specific pLDH test components, 
and the CareStart™ Malaria HRP2/pLDH (Pf/VOM) 
Combo RDT (#G0171) containing a P. falciparum HRP2 
and non-P. falciparum pLDH combination as per manu-
facturer’s recommendations. RDTs were selected for 
potential combined specificity for P. knowlesi detection 
[12].
Limit of detection
Samples with known parasite counts per microlitre of 
whole blood, determined by an expert research micros-
copist, were used to test the limit of detection of the Pan 
LAMP assay for P. knowlesi, P. falciparum and P. vivax, 
and the Pf LAMP assay for P. falciparum. Three samples 
of each relevant Plasmodium spp. were chosen. Frozen 
whole blood samples were thawed then diluted in fresh, 
malaria negative, non-endemic country whole blood to 
produce parasitaemias equivalent to 2000, 200, 20, 2, 
and 0.2 parasites/μL with the diluting blood serving as a 
negative control. These samples then had parasite DNA 
extracted using the different methods described above 
for each LAMP assay and conventional PCR, respectively.
Statistical analysis
Data were analysed by using STATA, version 12 (Stata-
Corp LP, College Station, TX, USA). Between-group 
differences were compared with Wilcoxon–Mann–
Whitney test for non-parametric data. PCR results were 
used as the gold standard. Test sensitivity was defined 
as true positives/(true positives  +  false negatives), and 
test specificity was defined as true negatives/(true nega-
tives  +  false positives); 95% confidence intervals were 
calculated using Wilson’s method.
Results
Baseline characteristics
Demographic, clinical and parasitological characteris-
tics of the patients are shown in Table 1. Median (IQR) 
parasitaemia was 1197/μL (300–3920) and 7246/μL 
(2299–17,232) for those with P. knowlesi and P. falcipa-
rum infection, respectively (p < 0.001).
LAMP
All 50 P. knowlesi samples were positive on the Pan LAMP 
and negative on the Pf LAMP. The 20 P. falciparum sam-
ples were positive in both assays. The 3 P. vivax samples 
were positive in the Pan LAMP assay. All 19 controls were 
negative in both assays. This gave a sensitivity of 100% for 
the Pan LAMP for P. knowlesi (95% CI 92.9–100), P. falci-
parum (95% CI 83.2–100) and P. vivax (95% CI 29.2–100). 
When combining results for Plasmodium genus detection 
overall, the Pan LAMP had both 100% sensitivity (95% CI 
95.1–100) and specificity (95% CI 82.4–100). For P. falci-
parum detection, the Pf LAMP also demonstrated both 
100% sensitivity (95% CI 83.2–100) and specificity (95% 
CI 94.8–100). All manual fluorescence and turbidity read-
ings were 100% concordant between observers and with 
the LAMP turbidimeter results.
Limit of detection
The limit of detection for P. knowlesi for both the Pan 
LAMP and specific PCR assays was 2 parasites/μL, with 
Table 1 Baseline characteristics, LAMP assay and  RDT 
results
Variable P. knowlesi P. falciparum
No. participants 50 20
Age
 Median 32 36
 (IQR) [range] (19–49) [3–72] (28.5–46.5) [19–73]
Gender
 Number male 38 13
 % 76 65
Parasite count/μL
 Geometric mean 1197 7246
 (IQR) [range] (300–3920) [43–46350] (2299–17232) 
[360–190912]
Severe
 n (%) 0 (0) 4 (20)
Pan LAMP
 Number positive (%) 50 (100) 20 (100)
 Sensitivity % (95% CI) 100 (92.9–100) 100 (83.2–100)




 Number positive (%) 0 (0) 20 (100)
 Sensitivity % (95% CI) 0 (0) 100 (83.2–100)
 Specificity % (95% CI) 0 (0) 100 (94.8–100)




 OptiMAL-IT® Pan pLDH
  n (%) [95% CI] 5 (10) [3.3–21.8] –
 OptiMAL-IT® Pf pLDH
  n (%) [95% CI] 3 (6) [1.3–16.5] –
 CareStart® non-Pf pLDH
  n (%) [95% CI] 14 (28) [16.2–42.5] –
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6/12 and 2/4 (50%) of replicates for each method, respec-
tively, also positive at 0.2 parasites/μL. For P. falciparum, 
the Pan LAMP limit of detection was 20  parasites/μL, 
with 8/12 (67%) and 5/12 (42%) of replicates also posi-
tive at 2 and 0.2 parasites/μL, respectively, compared to 
a limit of detection of 2 parasites/μL using specific PCR, 
with 3/4 (75%) of replicates also positive at 0.2 parasites/
μL. For P. vivax the limit of detection for both methods 
was 2 parasites/μL, with 9/12 (75%) and 2/4 (50%) of rep-
licates also positive at 0.2 parasites/μL for the Pan LAMP 
and specific PCR assays, respectively. For P. falciparum 
samples, the Pf LAMP also had a limit of detection of 
20 parasites/μL, with 3/6 (50%) of replicates also positive 
at 2 parasites/μL.
RDTs
For the P. knowlesi samples, the sensitivity of the pan-
pLDH test component in the OptiMAL-IT™ RDT was 
10% (95% CI 3.3–21.8; 5/50) and the CareStart™ non-P. 
falciparum pLDH was 28% (95% CI 16.2–42.5; 14/50). 
Three of the five P. knowlesi samples with a positive pan-
pLDH in the OptiMAL-IT™ RDT also tested positive 
to the P. falciparum-specific pLDH with the same band 
intensity.
Discussion
The Eiken Loopamp™ MALARIA Pan detection kit is 
highly sensitive, although inherently non-specific, for 
the diagnosis of uncomplicated knowlesi malaria, with 
100% sensitivity in the population studied, including 
clinical samples with parasite counts as low as 43  para-
sites/μL. The limit of detection for P. knowlesi using the 
Pan LAMP assay was low at 2 parasites/μL, comparable 
to PCR, and well below the threshold of detection for 
standard microscopy of approximately 50  parasites/μL 
[26]. Similar limits of detection were found for P. falcipa-
rum and P. vivax, which were also comparable to PCR. 
Sensitivity of the Pan LAMP for P. knowlesi detection far 
exceeded that of pLDH-based RDTs (OptiMAL-IT™ and 
CareStart™), with the sensitivity of these RDTs too low 
for clinical use, as previously reported [12].
As described with other LAMP systems, the technical 
benefits of this LAMP assay include its high sensitivity, 
stability at ambient temperature, and relatively simple use 
compared to other molecular diagnostic methods [16, 
17]. It requires no specialized equipment and minimal 
training, and is suitable for use in basic health facilities 
where accurate Plasmodium species confirmation would 
help to guide public health reporting, disease surveillance 
and in countries such as Malaysia, monitoring of national 
malaria elimination goals by 2020 [27].
This assay does however have some limitations. By defi-
nition, it is non-specific, with Pan LAMP shown to detect 
P. falciparum [18] and P. vivax [19], and therefore does not 
allow differentiation of P. vivax-infected patients requir-
ing additional liver-stage treatment. Nor does it identify 
co-infection in co-endemic areas [1, 28], hence the Pan 
LAMP does not offer an improvement in diagnostic spec-
ificity. The study design would also be improved by con-
ducting this evaluation in a field setting with fresh blood 
samples, however an expected decrease in sensitivity for 
either assay using thawed blood samples was not evident.
In the absence of appropriately sensitive and specific 
monoclonal antibodies for RDT, a specific P. knowlesi 
LAMP would aid diagnosis and surveillance in regional 
areas. Currently three LAMP assays have been designed 
specifically for P. knowlesi, targeting the β-tubulin [29], 
AMA-1 [30] and mitochondrial genes [17], respectively, 
with high sensitivity and specificity reported. However, 
these assays have not yet been utilized for clinical or 
surveillance purposes in endemic countries, particularly 
where PCR is available.
Conclusion
The Eiken Loopamp™ MALARIA Pan Detection kit had 
excellent sensitivity for the diagnosis of uncomplicated P. 
knowlesi infection, even in low parasitaemia samples, and 
may be a suitable tool for malaria surveillance. The limi-
tations of current RDTs and microscopy for P. knowlesi 
diagnosis means the development of a specific, field-
applicable, inexpensive rapid diagnostic tool to improve 
clinical malaria diagnosis in P. knowlesi-endemic coun-
tries, such as Malaysia, remains an important challenge.
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